secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001628280-23-016803
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zai Lab Q1 product revenue $62.8M, up 36% YoY; net loss narrows to $49.1M
-------------------------------------------------------------------------

- Product revenue $62.8M (+36% YoY); ZEJULA $42.7M (+44% YoY); Optune $13.3M; QINLOCK $1.3M; NUZYRA $5.5M.
- Net loss $49.1M ($0.05 per share) vs $82.4M loss ($0.09 per share) in Q1 2022.
- Cash $931.4M at March 31, 2023; R&D expense $48.5M, SG&A $62.5M.
- Josh Smiley promoted to President and COO effective April 1, 2023.
- Entered global license with MediLink for DLL3 ADC (ZL-1310) to expand lung cancer and oncology pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000162828023016803/0001628280-23-016803-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000162828023016803/zlab-20230509.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-016803

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer